Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - terbinafine - tablet - 250 milligram(s) - antifungals for systemic use; terbinafine

Սինգապուր - անգլերեն - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - basiliximab - injection, powder, for solution - 20 mg/vial - basiliximab 20 mg/vial

Իսրայել - անգլերեն - Ministry of Health

pfizer pharmaceuticals israel ltd - sirolimus - coated tablets - sirolimus 1 mg - sirolimus - rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. it is recommended that rapamune be used initially in combination with cyclosporine microemulsion and corticosteroids for 2 to 3 months. rapamune may be continued as maintenance therapy with corticosteroids only if cyclosporine can be progressively discontinued.

Իսրայել - անգլերեն - Ministry of Health

pfizer pharmaceuticals israel ltd - tofacitinib - tablets - tofacitinib 5 mg - tofacitinib - rheumatoid arthritis tofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards). tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate. psoriatic arthritis tofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy. ulcerative colitis tofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent ankylosing spondylitis tofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapyjuvenile idiopathic arthritis (jia) tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate.

Իսրայել - անգլերեն - Ministry of Health

pfizer pharmaceuticals israel ltd - tofacitinib - tablets - tofacitinib 5 mg - tofacitinib - rheumatoid arthritis tofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards). tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate. psoriatic arthritis tofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy. ulcerative colitis tofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent ankylosing spondylitis tofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapyjuvenile idiopathic arthritis (jia) tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate.

Միացյալ Թագավորություն - անգլերեն - MHRA (Medicines & Healthcare Products Regulatory Agency)

marlborough pharmaceuticals ltd - doxepin hydrochloride - oral capsule - 50mg

Միացյալ Թագավորություն - անգլերեն - MHRA (Medicines & Healthcare Products Regulatory Agency)

marlborough pharmaceuticals ltd - doxepin hydrochloride - oral capsule - 25mg

Միացյալ Թագավորություն - անգլերեն - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - doxepin hydrochloride - oral capsule - 25mg

Միացյալ Թագավորություն - անգլերեն - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - doxepin hydrochloride - oral capsule - 25mg

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - aliskiren hemifumarate 165.75mg equivalent to 150 mg aliskiren;  ;   - film coated tablet - 150 mg - active: aliskiren hemifumarate 165.75mg equivalent to 150 mg aliskiren     excipient: colloidal silicon dioxide crospovidone basic coating premix white basic coating premix red basic coating premix black magnesium stearate microcrystalline cellulose povidone - rasilez is indicated for the treatment of hypertension.